CORPORATE MEMBERS REPRESENTATIVE NOMINATIONS

2021 - 2023
# LIST OF CANDIDATES

<table>
<thead>
<tr>
<th>Nominees</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph PASSARELLI</td>
<td>Roche Diagnostics</td>
</tr>
<tr>
<td>Tricia RAVALICO</td>
<td>Abbott Diagnostics</td>
</tr>
</tbody>
</table>
1. NOMINATION

On behalf of: Roche Diagnostics

(Please insert name of your company)

Corporate Member of the International Federation of Clinical Chemistry and Laboratory Medicine,

I nominate:

Mr. Joseph Passarelli
Senior Director – Scientific Relations
Roche Diagnostics Operations
Centralized and Point of Care Solutions
Research and Development
9115 Hague Road
Indianapolis, Indiana 46250-0457

(Please insert title, name, company affiliation and address of nominee)

in the position of Corporate Representative on IFCC Executive Board for the 2021-2023 triennium.

Dr. Georg Kurtz
Head, R&D Homogeneous Assays and Lab Systems

(Please insert your own name and position within the company)

Signature: ____________________________
Date: ____________________________

2. ACCEPTANCE BY NOMINEE

I, Joseph Passarelli,

(Please insert title and name)

accept the above nomination. I declare that I am an employee of a Corporate Member of IFCC.

Signature: ____________________________
Date: ____________________________

3. CONSENT BY NOMINEE’S EMPLOYER

On behalf of: Roche Diagnostics

(Please insert name of company)

I confirm that we consent to the above nomination to the position of Corporate Representative on IFCC Executive Board for the 2021-2023 triennium.

Name: Dr. Joachim Eberle

Position in Company: Global Head of R&D Centralised and Point of Care Solutions

Signature: ____________________________
Date: ____________________________
4. POSITION STATEMENT BY NOMINEE (if desired)

Dear Corporate Member,

As the current Secretary to the IFCC Scientific Division Executive Committee and chair of the newly formed Task Force - Corporate Members (TF-CM), I would like to give you some information about who I am, my current roles, and why I have now decided to seek this position and ask for your support.

Who am I:

After studying biochemistry, I joined Roche Diagnostics in 1985 and have worked both domestically and internationally in research and development for more than 34 years in various roles. Currently I serve as Senior Director, Scientific Relations within the R & D organization. In this position, I represent Roche Diagnostics as scientific liaison to professional societies and standard- and guideline-setting organizations worldwide. A bit different than other corporate members, my primary responsibility is to work with, engage, support, participate, and focus on these organizations. Therefore, I believe I can devote more time and effort to the IFCC compared to other nominees because I am not burdened with many other competing responsibilities.

I have been actively engaged with the IFCC for 10 years. I believe over these last 10 years I have demonstrated to the IFCC and its corporate members my commitment to both entities. For 5 years I served as the corporate representative to the Scientific Division and now in the second year of my second term as its Secretary. This represents more than 9 years in total on the Scientific Division. Earlier this year I started as the chair of the newly formed IFCC Task Force - Corporate Members (TF-CM) with my first term ending at the end of 2021. The main goals of the TF-CM are to strengthen the collaboration between IFCC and its Corporate Members and to better address their specific needs and challenges, reporting directly to the Executive Board. In my nomination I explicitly stated that I wanted to lead this group because I have the firm belief that the IFCC could do more for its corporate members.

I am also a member of the Harmonization Oversight Group of the International Consortium for Harmonization of Clinical Laboratory Results (ICHCLR), with the IFCC acting as Secretariat.

In addition to these activities within the IFCC, I currently serve on the CLSI Board of Directors and prior to this, member of the CLSI Consensus Council. I am also a member of the Executive Committee of the US Technical Advisory Group to the International Organization for Standardization (ISO) Technical Committee 212 – Clinical laboratory testing and in vitro diagnostic test systems.

Why I am seeking this position and your support:

In addition to these official appointments, I have engaged with the IFCC Executive Board over the last many years on a number of key and strategic initiatives. I am firmly committed to driving these further and believe that corporate members are a key to the overall success of the IFCC. From my perspective I believe I am well networked with the other corporate members and associated companies, have their respect, and have the necessary executive skills and experience to now serve as their representative to the Executive Board.
Some initial topics I would intend to bring forward and already started within the TF-CM:

- Ways to improve communication and interaction between corporate members. This has been an ongoing problem with little change over the last many years. I am committed to exploring all approaches that would improve engagement among all corporate members.

- I have been vocal at General Conferences and in other settings that the IFCC should improve its engagement with regulators (FDA, EU, IVDR, IMDRF, etc.) and other organizations such as ISO, WHO, CLSI, etc. to try to harmonize the regulatory guidelines and processes and to reduce the regulatory burden for its member companies.

- I believe the IFCC could do more in promoting the value of laboratory testing in support of medical claims leading to reimbursement, and I am committed to moving this forward within the Executive Board.

- I also mentioned several times to the EB the need for clear and specific discussion of the value proposition when asking corporate members to provide funding including and beyond their yearly dues. Often funding requests come without information on "the why" and what will be gained by supporting companies. I hope to improve this situation if elected.

- To increase the impact of corporate membership and ultimately to increase support and funding to the IFCC, I believe one of the areas to explore is how to bring in new members beyond traditional diagnostic companies. Of course, Pharma comes to mind but there are many other "disruptive" companies / technologies (imaging, digitalization, miniaturization, just to name a few) that are entering into laboratory medicine. Increase of corporate membership is a win for every constituency within the IFCC.

These are just a few topics that come to mind. I am respectfully seeking your support and would kindly ask that you consider my experience and qualifications as you think about who to vote for to represent you on the Executive Board.

Thank you.

Sincerely and with best regards,

Joe Passarelli
Senior Director – Scientific Relations
Roche Diagnostics Operations
Centralized and Point of Care Solutions
Research and Development
9115 Hague Road
Indianapolis, Indiana 46250-0457
JOSEPH PASSARELLI  
Roche Diagnostics Operations  
9115 Hague Road, PO Box 50416  
Indianapolis, Indiana 46450-0416  
Tel. 1-317-521-4206 joseph.passarelli@roche.com

SUMMARY

Research and Development executive with over 30 years of domestic and international experience including discovery, development, operational planning, regulatory filings, and market commercialization. Background includes extensive experience in hapten/immunogen design, antibody engineering both in polyclonal and monoclonal forms, and in immunoassay development employing multiple technologies for homogenous laboratory-based testing platforms. Significant experience working directly with regulatory bodies and professional organizations such as the FDA, IFCC, AACC, Clinical and Laboratory Standards Institute – CLSI, ISO, EFLM, College of American Pathologists-CAP, RiliBÄK, and New York State reference standards. Known as a result driven, problem solver with an excellent record of implementing solutions and launching in vitro diagnostic products to markets worldwide.

PROFESSIONAL EXPERIENCE

Roche Diagnostics (division of Hoffmann-LaRoche)  
World leader in the fields of pharmaceuticals and medical in vitro diagnostic products, instrumentation, and services.

Senior Director – Scientific Relations  
Centralized and Point-of-Care Solutions, R & D  
May 2010 – Present

Represents the diagnostic division in the role as external technical liaison to organizations responsible for setting standards and guidelines (CLSI, IFCC, ISO, AACC, etc.) and to regulatory bodies worldwide.

Three-year appointment (second term 2018 – 2020) as Secretary to the Scientific Division of the Executive Committee of IFCC  
Chair IFCC Task Force – Corporate Members (TF-CM): first term 2019 – end 2021  
Secretary / Officer to the CLSI Board of Directors (first term 2020 - 2021)  
Member of the CLSI Consensus Council (2016 – 2017)  
Member of the CLSI Awards Committee (2015, 2016, 2017)  
Currently serving on a number of guideline subcommittees and working groups within both the CLSI and IFCC organizations.

Member of the Executive Committee of the US Technical Advisory Group to the International Organization for Standardization (ISO) Technical Committee 212 – Clinical laboratory testing and in vitro diagnostic test systems.

Member of the Harmonization Oversight Group (HOG) of the International Consortium for Harmonization of Clinical and Laboratory Results (ICHCLR).

Four-year appointment (2013 – 2016) as member of the CLSI Consensus Committee on Clinical Chemistry and Toxicology  
Roche corporate representative to IFCC, EFLM and ISO.
International assignment in Penzberg, Germany (2010 – 2013)

**Vice President – Professional Diagnostics - Drug Monitoring R & D**  
**January 2002 – April 2010**
Managed a team of approximately 60 scientists with an annual budget of over $10MM in the development and commercialization of diagnostic assay reagents, calibrators and controls in the areas of therapeutic drug monitoring, toxicology, drugs of abuse, and immunosuppressive drug monitoring for homogenous laboratory-based testing platforms. Product lines of responsibility comprised approximately $90MM in annual sales.
- Managed the assessment and recommendation of new technologies for small molecule quantitation in biological samples
- Facilitated targeted structured development processes early on resulting in more robust and predictable R & D performance and product quality
- Led all aspects of feasibility, early research, product design, development, scale-up, and transfer to manufacturing
- Responsible for all technical information required for FDA and worldwide regulatory approvals.
- Responsible for all technical aspects of multiple OEM collaborations
- Technical subject matter expert for domestic and international marketing, sales, and customer support.
- Principal liaison for all functional areas (contracting, legal, operations, instrument engineering, etc.) within the division.
- Liaison to external organizations / congresses, opinion leaders, and customers
- Served as a change leader in R & D to execute all corporate directives, performance management, leadership development, etc.

Successfully led the transfer of all U. S. based R & D functions and activities to Germany on time and on budget with the site closure in April 2010.

**Director - Centralized Diagnostics – Drug Monitoring R & D**  
**May 1998 – January 2002**
Led a group of approximately 15 scientists in the research, development and product commercialization of in vitro diagnostic tests for the quantitation of both drugs of abuse and therapeutic drugs in a variety of biological samples. Practical experience over three decades in the following areas:
- hapten / immunogen design
- antibody engineering
- immunoassay detection systems including isotopic, enzymatic, fluorescent, microparticle-based, binding proteins
- protein characterization and purification
- analytics including HPLC, LC/MS/MS, GC/MS
- calibrator and control development in urine, serum, whole blood and oral fluid matrices
- hollow fiber filtration and in all aspect of *in vitro* diagnostic reagent scale-up and manufacturing
packaging and labeling design
requirements / documentation for worldwide regulatory approvals including the FDA and IVD Directive

Multiple Positions - Centralized Diagnostics – Drug Monitoring R & D
Principal Scientist: October 1990 – July 1992
Research Scientist: May 1988 – October 1990
Scientist: October 1985 – May 1998

New York University Medical Center
Endocrine Division
Senior Research Assistant
June 1980 – October 1985
Academic position focused on brain peptides, hormones, and protein chemistry research.

EDUCATION
B.A., Biochemistry, Canisius College, Buffalo, New York
Graduate course work in Chemistry and Biochemistry, New York University, New York

PROFESSIONAL MEMBERSHIPS
AACC- American Association of Clinical Chemists
IATDMCT- International Association of Therapeutic Drug Monitoring and Clinical Toxicology

PUBLICATIONS


Brenneisen R; Elsohly M A; Murphy T P; Passarelli J; Russmann S; Salamone S J; Watson D E, “Pharmacokinetics and excretion of gamma-hydroxybutyrate (GHB) in healthy subjects”, Journal of Analytical Toxicology, 28 (8) p625-30 (2004)

Passarelli J; Bates M, A “Clinical laboratory automation system for drugs-of-abuse monitoring”, American Clinical Laboratory, 16 (8) p8-9 (1997)
Salamone S J; Honasoge S; Brenner C; McNally A J; Passarelli J; Goc-Szkutnicka K; Brenneisen R; ElSohly M A; Feng S, “Flunitrazepam excretion patterns using the Abuscreen OnTrak and OnLine immunoassays: comparison with GC-MS”, Journal of Analytical Toxicology, 21 (5) p341-5 (1997)

Brenner C; Hui R; Passarelli J; Wu R; Brenneisen R; Bracher K; ElSohly M A; Ghodoussi V D; Salamone S J, “Comparison of methaqualone excretion patterns using Abuscreen ONLINE and EMIT II immunoassays and GC/MS”, Forensic Science International, 79 (1) p31-41 (1996)

Yokoe T; Audhya T; Brown C; Hutchinson B; Passarelli J; Hollander C S, “Corticotropin-releasing factor levels in the peripheral plasma and hypothalamus of the rat vary in parallel with changes in the pituitary-adrenal axis”, Endocrinology, 123 (3) p1348-54 (1988)


Audhya T; Manzione M M; Nakane T; Kanie N; Passarelli J; Russo M; Hollander C S, “Levels of human and rat hypothalamic growth hormone-releasing factor as determined by specific radioimmunoassays systems”, Proceedings of the National Academy of Sciences of the United States of America, 82 (9) p2970-4 (1985)

Hollander C S; Audhya T; Russo M; Passarelli J; Nakane T; Schlesinger D, “Levels of corticotropin releasing factor-like immunoreactivity in mammalian hypothalamic and extrahypothalamic brain tissue as determined with a monoclonal antibody to the ovine material”, Endocrinology 112 (6) p2206-8 (1983)

**ABSTRACTS**

Dorn A R; Tsai J; Mountain L; Phillips M; Rugaber J; Zhou J; Skidmore C; Mann B; Passarelli J, “Assessment of total and free mycophenolic acid in transplant patient plasma by enzyme receptor assay”, Therapeutic Drug Monitoring, V27, N2, APR, pp 216-217, Presented at the 9th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Louisville, Kentucky, USA (2005)

Lawrence C C; Thomas A; Shastri S; Yuan W; Jones T; Ghoshal M; Hui R; Sigler G; Hosein B; Passarelli J, “An automated microparticle agglutination immunoassay for the therapeutic drug monitoring of nelfinavir”, Therapeutic Drug Monitoring, V27, N2, APR, p 232, Presented at the 9th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Louisville, Kentucky, USA (2005)
Yuan W; Lawrence C C; Hosein B; **Passarelli J**, “Simultaneous quantitative determination of eleven antiretroviral agents in human plasma using HPLC with UV detection in conjunction with automated sample preparation”, Therapeutic Drug Monitoring, V27, N2, APR, p 261, Presented at the 9th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Louisville, Kentucky, USA (2005)


Dorn A R; Mountain L D; Phillips M; Rugaber J; Tsai S; Zhou J; Stiasny D; **Passarelli J**, “Roche Diagnostics automated clinical analyzer enzyme/receptor assay for total and free mycophenolic acid measurement in transplant patient samples”, Clinical Chemistry, vol. 50, no. 6, Suppl. S, Part 2, p. A134, Presented at the 56th Annual Meeting of the American Association for Clinical Chemistry (AACC), Los Angeles, California, USA (2004)

Ghoshal M; Sigler G; Root R; Ouyang A; Schamerloh A; Mutchler C; Tsai J; **Passarelli J**, “Novel ecstasy class derivatives and reagents for immunoassays”, Abstracts of Papers American Chemical Society 228 (Part 2): p U144-U145, Presented at the Meeting of the Division of Chemical Toxicology of the American Chemical Society held at the 228th National Meeting of the American Chemical Society, Philadelphia, PA, USA (2004)

Ghoshal M; Sigler G; Root R; Ouyang A; Arabshahi L; Schamerloh A; Goodman J; Hippensteel E; Tsai J; **Passarelli J**, “Reagents for efavirenz immunoassay”, Abstracts of Papers American Chemical Society 228 (Part 2): p U145, Presented at the Meeting of the Division of Chemical Toxicology of the American Chemical Society held at the 228th National Meeting of the American Chemical Society, Philadelphia, PA, USA (2004)

Corbett T; West C; Mann B; Moorman D; **Passarelli J; Jordan S L**, “Carbamazepine ONLINE (R) TDM assay performance on the Roche/Hitachi analyzers”, Therapeutic Drug Monitoring, V25, N4, AUG, p 497, Presented at the 8th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Basel, Switzerland (2003)

West C; Corbett T; Golden D; **Passarelli J; Jordan S L**, “Phenobarbital ONLINE (R) TDM assay performance on the Roche/Hitachi analyzers”, Therapeutic Drug Monitoring, V25, N4, AUG, p 498, Presented at the 8th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Basel, Switzerland (2003)

Klinedinst L; Bittner L; Parks J; Bates P; Moorman D; Motter K; **Passarelli J**, “Valproic acid ONLINE (R) TDM assay performance on the Roche/Hitachi analyzers”, Therapeutic Drug Monitoring, V25, N4, AUG, p 498, Presented at the 8th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Basel, Switzerland (2003)
Dorn A R; Mountain L D; Phillips M; Rugaber J; Zhou J; Stiasny D; Passarelli J, “Roche Diagnostics automated clinical analyzer enzyme/receptor assay for mycophenolic acid measurement in transplant patient samples”, Therapeutic Drug Monitoring, V25, N4, AUG, p 510, Presented at the 8th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology, Basel, Switzerland (2003)


Ghoshal M; Sigler G; Tsai J; Gerbig R; Arabshahi L; Hoang M; Schamerloh A; Salamone S J; Passarelli J, “Use of site-selective gentamicin derivative in Roche TDM online gentamicin immunoassay”, Abstracts of Papers American Chemical Society 226 (1-2): p ORGN 537, Presented at the 226th ACS (American Chemical Society) National Meeting, New York, NY, USA (2003)


Jordan S L; Golden M D; Henry J; Corbett T; West C; Hui R; Passarelli J, “Phenytoin ONLINE(R) TDM assay performance on the Roche/Hitachi 917 analyzer”, Clinical Chemistry 48 (S6): p A48, Presented at the 54th Annual Meeting of the American Association for Clinical Chemistry (AACC), Orlando, Florida, USA (2002)

Bender J; Motter K; Antalis C; Skidmore C; Hamilton L; Moorman D; Passarelli J, “Digitoxin ONLINE(R) TDM assay performance on the Roche/Hitachi 917 analyzer”, Clinical Chemistry 48 (S6): p A44, Presented at the 54th Annual Meeting of the American Association for Clinical Chemistry (AACC), Orlando, Florida, USA (2002)

Zhao H; Yarbrough S; Zhao Y; Wiler B; Passarelli J; Moellers C; Salamone S J, “Online AMPSX assay with improved detection sensitivity to MDMA on Roche COBAS INTEGRA analyzers”, Clinical Chemistry 47 (S6): p A73, Presented at the 53rd Annual Meeting of the AACC/CSCC, Chicago, Illinois, USA (2001)

Dewees K S; Klinedinst L K; Banno J; Motter K; Passarelli J; Salamone S J, “Performance of the Roche cyclosporine assay on the COBAS INTEGRA 400 analyzer”, Clinical Chemistry, 46, N6, 2., p 778, Presented at the 52nd Annual Meeting of the American Association of Clinical Chemistry, San Francisco, California, USA (2000)

Mendoza K S; Banno J; Motter K; Passarelli J; Salamone S J, “Performance evaluation of the Roche cyclosporine assay on the COBAS(R) INTEGRA 700”, Clinical Chemistry


Brandle-O'Connor J; Bates M; Blake-Courtney J; Brenner C; Casaretto E; **Passarelli J**, Vitone S; Salamone S J, “Abuscreen Online immunoassay for the detection of benzoylecgonine in urine on the COBAS MIRA”, Clinical Chemistry 37 (6): p 996, Presented at the 43rd National Meeting of the American Association for Clinical


Audhya T; Kanie N; Nakane T; Manzione M; Passarelli J, “Hypothalamic growth hormone releasing factor immunoreactivity (GRF-LI) in human and rat tissue: quantitative and localization”, Endocrinology, page 327, Presented at the 7th International Congress of Endocrinology, Quebec City, Canada (1984)


Audhya T; Manzione M; Nakane T; Passarelli J, “High corticotropin releasing factor-like immunoreactivity (CRF-LI) in tissues outside the brain and in peripheral plasma of the rat”, Clinical Research, 32: p 260 A, Presented at the 76th Annual Meeting of the American Society of Clinical Investigation, Washington, D.C., USA (1984)


Trica
RAVALICO

1. NOMINATION
On behalf of: Abbott Diagnostics
(Please insert name of your company)
a Corporate Member of the International Federation of Clinical Chemistry and Laboratory Medicine.

I nominate: Tricia Ravalico
Director of Global Scientific Leadership
Abbott Diagnostics
100 Abbott Park Road, CP1.5, Abbott Park, IL 60064
Tricia.Ravalico@abbott.com

to the position of Corporate Representative on IFCC Executive Board for the 2021-2023 triennium.

Signature / Date

2. ACCEPTANCE BY NOMINEE

Tricia Ravalico, Director of Global Scientific Leadership
accept the above nomination. I declare that I am an employee of a Corporate Member of IFCC.

Signature / Date

3. CONSENT BY NOMINEE’S EMPLOYER

On behalf of: Abbott Diagnostics

I confirm that we consent to the above nomination to the position of Corporate Representative on IFCC Executive Board for the 2021-2023 triennium.

Name: Jaime Contreras
Senior Vice President, Core Lab Diagnostics, Commercial Operations, Abbott

Signature / Date
4. POSITION STATEMENT BY NOMINEE (if desired)

Dear IFCC Executive Board,

I am excited at the possibility of becoming the Corporate Representative on the IFCC Executive Board for the 2021-2023 term. Thank you in advance for your time and consideration.

As the Abbott corporate representative for IFCC, I have been exposed to the many GREAT initiatives led by the IFCC to advance laboratory medicine worldwide. It has been an honour to endorse and support valued programs including the Abbott-IFCC VLP program and multiple IFCC distinguished awards. Since assuming responsibility as the Abbott corporate representative for IFCC within the last 3 years, Abbott’s participation on IFCC committees, task forces and working groups have increased by more than 2-fold.

My long-time experience with the IFCC, however, predates my role as a corporate representative, with the most significant long-term contributions being associated with my 9-year support to the IFCC CCB (which was formerly the IFCC Task Force on the Clinical Education on Cardiac Biomarkers). Key initiatives for that effort began under Dr. Jordi Ordonez (chaired for 2-terms) and more recently, with Dr. Fred Apple, (recently approved for his 2nd term as chair) leading to multiple publications and reference documents which are currently attributed to the most downloaded documents on the IFCC website. As the lead of the IVD team within the IFCC CCB, we developed and activated annual joint industry-sponsored workshops, with strong collaboration and partnerships across 6 IVD companies working together for unbiased education on complex topics for the betterment of Lab Medicine.

I currently also serve on the IFCC Executive Committee for the Communications and Publication’s Division. During this time, I have had the privilege of being part of valued social media efforts including increasing contributions to eNEWS, supporting commercial feedback on annual surveys and most recently, brainstorming enhancements/next steps with the e-Academy and eIFCC Journal.

From an Industry perspective, I am been active in the field of lab diagnostics since 1996. With over 23 years in the diagnostic industry, I have held leadership positions in R&D, Medical Affairs, Scientific Affairs, Global Marketing, and Business Development. For the past 5 years, I have been leading the Global Scientific Leadership team with the goal of elevating and quantifying the value of Lab Medicine through integrated clinical care programs with measurable benefits to patients, payors, clinicians and health systems. These efforts have led the development and management of the UNIVANTS of Healthcare Excellence Program, a global prestigious award program designed to inspire and recognize global best practices that elevate current standards of care. The IFCC is a key partner to this initiative, among 7 other leading healthcare organizations, including Abbott.

I am very much attracted to this leadership role on the IFCC Executive Board as my passion to support the IFCC has only grown stronger with time. I believe in the value proposition of the IFCC and in our joint ability to advance lab medicine for the betterment of patient care worldwide. I am a strong communicator, active collaborator and passionate contributor in all projects and programs that I endorse. I would be honoured to expand my role within the IFCC with the hopes of increasing IVD participation within the IFCC across the globe, facilitating the support of new corporate members, and managing the industry voice of IVD to the executive board for highly effective programs and continued success in the new terms ahead.

I look forward to working with all of you more closely in the months ahead and want to thank all members of the IFCC EB for their valued time, amazing support and for considering me as a potential candidate for this valued 2021-2023 Corporate Representative in the EB.

Let’s make this happen!
Tricia Ravallio
November 21, 2019

International Federation of Clinical Chemistry and Laboratory Medicine

Attr: Nominations Committee

This letter is in support of the nomination of Patricia Ravallio for the position of IFCC Corporate Member Representative to the next Executive Board. In my position of Divisional Vice President of Medical Affairs at Abbott, I have had the pleasure working with Patricia for over 10 years. During that period, I have constantly been impressed with both the energy she brings to all endeavors and her dedication to in vitro diagnostic testing and laboratory medicine. Her work in supporting the UNIVANTS program which brings recognition to healthcare systems that have utilized laboratory medicine in making patient care improvements is just one example.

Patricia’s extensive 20-year background in the diagnostics industry makes her uniquely suited for this position. She has held positions in research and development, clinical research, laboratory customer support and scientific leadership. Her level of commitment and performance has been recognized at Abbott with multiple high-level awards. In addition to her contributions to Abbott, she has served on multiple IFCC committees since 2012.

In summary, I believe Patricia Ravallio will bring the same energy, dedication and value to the IFCC Corporate Member Representative position that she has done at Abbott.

David K. Spindell, MD
Divisional Vice President Medical Affairs

Abbott
APromise for Life
Tricia H. Ravalico  
1605 Woody Creek Drive, Keller, TX 76248  
Cell: 469-964-5002 ● Home: 817-577-9438 ● TJHR22@gmail.com

Dynamic, and driven professional with over 24 years of diverse scientific, medical and marketing experience in diagnostic assays and systems. Customer-focused with strong leadership and communication skills. Strategic thinker, Agile, Self-motivated & Passionate. Active volunteer to AACC, IFCC and EHMA.

REPRESENTATIVE CORE COMPETENCIES

- Strategic Marketing  
- KOL Development  
- Scientific Affairs  
- Assay Development  
- People Management  
- Program Management  
- Global Communications  
- Creative Development  
- Problem Solving  
- System Integration  
- Clinical Studies  
- Demand Creation

REPRESENTATIVE PROFESSIONAL HONORS

2018 ADD DVP AWARDS from Global Marketing (Healthcare Excellence)  
2017 ADD DVP AWARDS from R&D and Global Marketing (Cardiac Screening Strategy and Alinity Scientific Program)  
2016 ADD PRESIDENTS AWARD; Cardiac Collaboration Efforts with ADD and APOC  
2016 US PATENTGRANT #9,308,506 Clinical Analyzer and Wash Method  
2014 DONALEE TABERN OUTSTANDING RESEARCH TEAM AWARD: Medical Research Group  
2013 ADD RESEARCH EXCELLENCE AWARD: hsTnI Education and Worldwide Launch Support  
2012 ADD RESEARCH EXCELLENCE AWARD: hsTnI Strategic Clinical Development  
2010 ADD GLOBAL MARKETING EXCELLENCE AWARD: Product Manager of the Quarter (Cardiac, Q4)  
2009 ADD GLOBAL MARKETING EXCELLENCE AWARD: Line of Business of the Quarter (Cardiac, Q2)  
2008 AACC OUTSTANDING SPEAKER AWARD: Abbott Clinical Chemistry Workshop Presenter  
2006 ADD TAB ci600 TEAM EXCELLENT AWARD: Leadership/Instrument Development  
2005 PRESIDENT and VICE-PRESIDENT AWARDS: ARCHITECT LabCorp Validation Project  
2005 TECHNOLOGY PATENT FILING: Probe Washing Method in a Clinical Tester  
2004 DEPARTMENT and STAFF AWARDS: Customer START Stabilization, Innovation in Design  
2003 ADD ENTREPRENUERIAL AWARD: ARCHITECT ci8200 Project Integration Team  
2002 ADD SCIENCE AWARD: ENGINEER of the YEAR

PROFESSIONAL EXPERIENCE

Director, Scientific Leadership, Global Marketing ...........................................January 2015 – present  
Abbott Laboratories, Irving, Texas

Core Job responsibilities:

- Develops and leads Global Scientific Marketing Strategies for differentiated and enhanced scientific brand reputation
- Manages International team including roles, responsibilities and financial budgets with year over year history of surpassing business needs
- Collaboratively interfaces across teams, both geographically and professionally for actionable insights and outcomes
- Develops, leads and implements high impact educational strategies at key conferences and congresses globally
- Facilitates strong relationships with key opinion leaders, facilitating expert advisory forums/ speaking programs
- Identifies new contacts, partners and innovative projects that enhance scientific collaborations and novel ideas with most recent success associated with the UNIVANTS of Healthcare Excellence Program
- Influences global guidelines and drives enhanced industry participation on recognized committees (i.e., IFCC CPD, IFCC CCB, AACC CAB, CLSI, etc.)
- Supports area needs with scientific resources and expertise to meet business needs
Assoc. Director, Medical Research Group, Medical Affairs…….January 2011 – December 2014
Abbott Laboratories, Irving, Texas

Core Job responsibilities:
- Sought and oversaw 45+ global clinical trials for high sensitive troponin-I.
- Developed and implemented pre-launch strategic clinical development plan(s) to ensure novel biomarker acceptance with evidence-based value-added positioning to physicians and laboratories.
- Collaborated with key opinion leaders and facilitate global clinical research studies in accordance with strategic plan.
- Drove educational efforts and influence global guidelines via participation on recognized committees (i.e., International Task Force Initiatives) and through medical discussions and clinical collaborations.
- Supported critical customer needs with field travel and educational lectures and/or discussions as requested.
- Consulted with other Abbott divisions to support new product development and regulatory submission strategies for key products.
- Hosted advisory discussions with world experts as appropriate to seek new clinical indications for existing and novel biomarkers in development.

Senior Product Manager, US and Global Marketing……………August 2007 – December 2010
Abbott Laboratories, Irving, Texas

Core Job responsibilities:
- Responsible for driving worldwide cardiac demand (1,497 MM TAM) for Abbott diagnostic products through increased utilization of cardiac biomarkers at existing customer accounts and by using cardiac to leverage new instrument and assay placements.
- Successfully manages project initiation and spending implementation via oversight and responsibility for the Cardiac and CMR (Cardiac, Metabolic, Renal) budgets, totally ~700K annually.
- Represents customer needs for the development of assay design input requirements and/or customer communications. Participates in cross-functional team settings to drive the ADD LRP and strategically define programs and assay futures related to Cardiac and Core Lab Initiatives.
- Educated global commercial areas on the key findings and benefits of critical clinical studies to drive evidence and utilization of select biomarkers.
- Developed and launched a valued, strategic overarching brand strategy for Cardiac Metabolic & Renal Biomarkers (Simple Solutions for Complex Patients) with physician and laboratory messaging via general and specialized sales teams. Program success has enhanced global biomarker utilization, improved ADD customer image, strengthened and developed relations with influential opinion leaders, and consistently enables opportunity for ADD differentiation.
- Exceeded 2009 and H1 2010 YTD global margin and sales for cardiac with International growth outpacing cardiac market (14%) and all other ADD immunoassay lines of business, including and excluding core laboratory.

Abbott Laboratories, Irving, Texas

- Prepared and delivered educational lectures on diagnostic products and various disease states including cardiac, clinical chemistry, infectious disease, instrumentation and workflow.
- Led specialized scientific discussions with laboratory pathologists and technical specialists.
- Strengthened and developed clinical and laboratory key opinion leaders for consulting and/or scientific partnerships.
- Sought and led clinical study collaborations including protocol development, participation and publication of findings.
- Interacted regularly with existing & prospective customers while providing internal guidance & training to ADD sales.
- Active involvement in scientific procurement of GPO contract acceptance including Premeir, Broadlane, & Novation.
- Assisted in the development of technical marketing brochures to promote/protect/differentiate key products.
- Travelled routinely to domestic customer sites for scientific support preceding or following a commercial sale.
Tricia H. Ravalico

Senior Engineer, Systems Integration ................................. September 2000 – January 2006
Abbott Laboratories, Irving, Texas

- Managed 8 scientists within Clinical Chemistry System R&D, and participated in cross-functional teams for enhanced product development and technical innovation
- Led internal and external characterization studies on assay and system performance. Directed 8-month ARCHITECT LabCorp Validation Project, achieving first-time permission for Abbott customer platform acceptance
- Authored technical abstracts and posters relating to new discovery, characterizations and design. Optimized the sample probe wash for the ARCHITECT ci8200 to achieve product requirement design goal for sample-to-sample carryover. Significantly improved sample probe washing on the AEROSET system.
- Provided immediate and technical troubleshooting support to critical ARCHITECT customer accounts and lead regular worldwide conference calls as part START initiative to stabilize valued accounts.
- Identified, communicated and documented software, system and process enhancements pertaining to product requirements, field concerns, process improvements or customer complaints.
- Developed, implemented and analyzed feasibility, verification and validation data for ARCHITECT and AEROSET System Integration Testing.

Assay Applications Specialist, Clinical Chemistry .......................... June 1997 – August 2000
Abbott Laboratories, Irving, Texas

- Optimized test parameters of clinical chemistry assays for AEROSET, a random access, automated new system
- Taught assay application development to customers, internal scientists and worldwide assay specialists
- Wrote technical abstracts and attended clinical chemistry conventions
- Supported ADD clinical research studies via direct customer interaction as well as troubleshooting support to clinical research monitors.
- Provided technical training, guidance and troubleshooting to customers, sales and other Abbott sites
- Lead project teams for assay characterizations with studies including linearity, limit of quantitation, limit of detection, antigen-excess, and dilution recovery.
- Assume role of Project Coordinator for value assigning multi-constituent clinical chemistry calibrators

Abbott Laboratories, Irving, Texas

- Applied technical analysis to system verification testing to recommend hardware design modifications that would better meet business needs without compromising product quality
- Ensured compliance with divisional and site quality standards, policies and procedures

Abbott Laboratories, Chicago, Illinois

- Ran offline immunoassay tests (FPIA and MEIA) with human serum samples to verify the absence of and/or quantify/mitigate the presence of reagent cross-contamination among new and on-market assays.
- Created and optimized kitting/processing loadlists for offline AxSYM test protocols
- Tracked, ordered and created monthly reports for department reagents, calibrators, controls and consumables
- Analyzed offline AxSYM data using a UNIX-based program to statistically test for reagent cross-contamination
Graduate Student, Independent Researcher ............................ March 1995 – November 1995
University of Illinois, Chicago

- Screened for potential putative co-activators of tissue specific liver transcription factor subunit via two-yeast hybrid interaction
- Experienced in electroporation and yeast/DNA co-transformations

Associate Scientist, Molecular Biology, DuPont Merck Pharma., ........ May 1995 – August 1995
Glenolden, PA

- Specialist in the cloning and characterization of a DNA ligase I active site mutant and in the optimized purification of the wild type gene
- Techniques developed: Oligo purification, in-vitro and in-vivo characterization, chromatography, electroporation, PAGE and native gel analysis

Research and Teaching Assistant, Penn State University .................. August 1992 – April 1995
Pennsylvania State Biotechnology Lab, University Park, PA

- Experienced in DNA sequencing, PCR, molecular cloning, coupled transcription/translation reactions, PAGE and native gel analysis of protein and DNA complexes.
- Specialized in tissue culture of apple transgenic plants
- Assistant-directed a PSU tissue culture workshop on apple transformation and gene gun transduction

Protein Biochemistry, SmithKline Beecham Pharmaceuticals .......... May 1994 – August 1994
King of Prussia, PA

- Experienced in ion exchange chromatography, affinity chromatography, gel filtration, membrane capture and western blotting techniques
- Specialized in the effects of de-glycosylation on protein solubility in the purification efforts of two proteins

EDUCATION

Pennsylvania State University, University Park, PA .......................... August 1991 – May 1995
BS Biochemistry, College of Science

Phi Sigma Pi National Honor Society, Dean’s List, Garden State Scholar, Reimen Scholarship, University of Illinois Graduate Scholarship

PROFESSIONAL COMMITTEES and AFFILIATIONS

AACC (American Association of Clinical Chemistry); Member and Serves on Corporate Advisory Board
IFCC (International Federation of Clinical Chemistry); Member and Chair/Participant on multiple Committees
CLSI (Clinical and Laboratory Standards Institute); Member and 2007 Appointment to 2 Writing Committees
EHMA (European Health Management Association); Service on 2019 Advisory Board for 2020 Annual Meeting
PUBLICATIONS/ABSTRACTS/POSTERS


- Room Temperature and Refrigerated Storage Stability of Five Commonly Measured Analytes (C-93), P. C. Painter1, R. S. Newby1, D. M. Hoefner2, T. Ravalico3. 1Dynacare Tennessee Laboratory, U.T. Medical Center, Knoxville, TN, 2LabCorp, Elon, NC, 3Abbott Laboratories, Irving, TX, Clin Chem Vol 45, No. 6, Supplement, 2006.


- ARCHITECT c16000 Clinical Chemistry Analyzer Subsystem-Level Performance, C. Wilson1, T. Onuma2, Y. Lemma1, T. Ravalico1, G. Osikowiscz2 et. al., 1Abbott Laboratories, Irving, TX, 2Toshiba Medical, Tokyo, Japan, 3Abbott Laboratories, Chicago, IL. Clin Chem Vol 45, No. 6, Supplement, 2006.


